1069088-27-2 Usage
Uses
Used in Pharmaceutical Industry:
(S)-N-(2,4-Dichlorobenzyl)-3-methyl-2-oxoimidazolidine-4-carboxamide is used as a potential therapeutic agent for various medical conditions due to its antibacterial, antifungal, and anti-inflammatory properties. Its specific structure, including the 2,4-dichlorobenzyl group, may enhance its effectiveness in treating certain infections and inflammations.
Used in Research and Development:
(S)-N-(2,4-Dichlorobenzyl)-3-methyl-2-oxoimidazolidine-4-carboxamide is used as a subject of study in the field of medicinal chemistry and pharmacology. Researchers are investigating its potential uses and mechanisms of action to better understand its biological activities and to develop new pharmaceuticals with improved efficacy and safety profiles.
Further research is necessary to fully comprehend the potential applications and mechanisms of (S)-N-(2,4-Dichlorobenzyl)-3-methyl-2-oxoimidazolidine-4-carboxamide, but its unique properties and structure make it a promising candidate for future pharmaceutical development.
Check Digit Verification of cas no
The CAS Registry Mumber 1069088-27-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,9,0,8 and 8 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1069088-27:
(9*1)+(8*0)+(7*6)+(6*9)+(5*0)+(4*8)+(3*8)+(2*2)+(1*7)=172
172 % 10 = 2
So 1069088-27-2 is a valid CAS Registry Number.
1069088-27-2Relevant academic research and scientific papers
Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor
Abberley, Lee,Bebius, Aude,Beswick, Paul J.,Billinton, Andy,Collis, Katharine L.,Dean, David K.,Fonfria, Elena,Gleave, Robert J.,Medhurst, Stephen J.,Michel, Anton D.,Moses, Andrew P.,Patel, Sadhana,Roman, Shilina A.,Scoccitti, Tiziana,Smith, Beverley,Steadman, Jon G.A.,Walter, Daryl S.
scheme or table, p. 6370 - 6374 (2010/12/18)
A backup molecule to compound 2 was sought by targeting the most likely metabolically vulnerable site in this molecule. Compound 18 was subsequently identified as a potent P2X7 antagonist with very low in vivo clearance and high oral bioavailability in all species examined. Some evidence to support the role of P2X7 in the etiology of pain is also presented.
